Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Synergistic Real-world Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors TKIs in the Treatment of Advanced Non-small Cell Lung Cancer NSCLC Retrospective Study

Next Previous
X
Search
Trial Profile

Synergistic Real-world Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors TKIs in the Treatment of Advanced Non-small Cell Lung Cancer NSCLC Retrospective Study

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Dacomitinib (Primary) ; Elemene (Primary) ; Elemene (Primary) ; Erlotinib (Primary) ; Gefitinib (Primary) ; Icotinib (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SELECT-1

    • Most Recent Events

    • 26 Dec 2023 Planned End Date changed from 30 Aug 2023 to 30 Mar 2026.
    • 15 May 2023 Planned End Date changed from 30 Mar 2023 to 30 Aug 2023.
    • 15 May 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top